Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fd1de475659cdc01fa8d1d7b9c8596b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_661b93cf25aebb1551539d3b1dc2636b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8778713427f3c00296d87dcb061a063e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9a53e6ac3c6802f03783abb3cc121a9 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate |
2011-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaed355980118a6f393bc525c37a97d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b5d5ee831a6e2d5641fe4339bfcd29c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a35c4ffd71b1f4a720642415c9178e47 |
publicationDate |
2012-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2012100154-A1 |
titleOfInvention |
Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration |
abstract |
Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023148346-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018112264-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10980739-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020106757-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020106704-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020106750-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020106754-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4252629-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9681647-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014008385-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015164053-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021119482-A1 |
priorityDate |
2002-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |